Drug Repurposing Market is to grow at an 4.9 % CAGR, with the United States leading the market through 2032

Drug Repurposing Market to Hit USD 51.80 Bn by 2032  

The Drug Repurposing Market was USD 35.33 Bn in 2024 and is expected to expand at a CAGR of 4.9 % from 2025 to 2032, reaching USD 51.80 Bn by 2032. The U.S. FDA approved Bristol-Myers Squibb’s medication Cobenfy, which was first studied for Alzheimer’s disease before being repurposed for schizophrenia. This was a major milestone in drug repurposing. In 2023, North America dominated the drug repurposing market, generating 46.3% of total sales and valued at USD 14.8 billion.

Drug repurposing allows the use of medications that are already approved and have passed clinical testing, greatly cutting down on the time and expense needed for development compared to creating new medications from scratch. Repurposing current medications can help treat certain disorders more quickly than developing new treatments, which could take years. Advancements in big data analytics, artificial intelligence, and computational techniques allow for the quicker discovery of possible drug repurposing candidates. Regulatory agencies, like the U.S. FDA and EMA, provide incentives for repurposing drugs, such prolonged patent exclusivity, orphan drug classification, and expedited clearances.

To Know More about this report  Request A Free Sample Copy: https://www.maximizemarketresearch.com/request-sample/273130/ 

Drug Repurposing Market Segmentation

By Type of Approach: Disease-Centric Approach is frequently used to repurpose medications for complicated or uncommon illnesses like cancer, neurological conditions, and infectious diseases. The Target-Centric Approach focuses on certain biological processes or entities (such genes or proteins) involved in a disease. The Drug-Centric Approach focuses on analysing the characteristics and modes of action of specific drugs.

By Drug Molecules: Biologics are Large, intricate molecules usually derived from living things. These include gene treatments, cell therapies, recombinant proteins, vaccinations, and monoclonal antibodies. Small-molecule drugs are simpler in structure and made up of fewer atoms than biologics, usually having a molecular weight of less than 900 Da.

Drug Repurposing Market Regional Analysis

United States: The Drug Repurposing Market in the United States is anticipated to expand at a CAGR of around 4.5% between 2025 and 2032. This suggests that the market could exceed $50 billion by 2032. TxGNN is an AI model evaluating medications for more than 17,000 illnesses, there is a significant chance to increase the number of medicinal applications available in the US market. Novartis AG and Pfizer Inc. are the key players that dominate the drug repurposing market in the US.

Germany: The German market is expected to increase at a CAGR of 10.69%, indicating substantial growth potential in the coming years. Major contributions came from areas like Baden-Württemberg, North Rhine-Westphalia, and Bavaria. Innovation and manufacturing in the repurposed pharmaceuticals industry are particularly strong in Bavaria. Bayer AG, Boehringer Ingelheim, and Merck KGaA, Darmstadt are key players dominating the German market.

China: Shanghai Fosun Pharmaceutical (Group) Co., Ltd is a well-known Shanghai, China-based pharmaceutical and healthcare corporation that is focused on innovation. Fosun Pharma reported RMB 30.91 billion in sales for the first three quarters of 2024, representing an uneven 5.74% year-over-year rise. Research and development operations accounted for RMB 2.65 billion of Fosun Pharma’s RMB 3.92 billion in the first three quarters of 2024.

Drug Repurposing Market Competitive Landscape

Bayer AG: In March 2025, Bayer entered into a global license agreement with China’s Puhe BioPharma. In November 2024, Cytokinetics and Bayer collaborated to get certain rights in Japan for €50 million.

Boehringer Ingelheim: In July 2024, Boehringer Ingelheim acquired Nerio Therapeutics Inc. for approximately $1.3 billion. In November 2023, Boehringer Ingelheim acquired T3 Pharmaceuticals to broaden its immuno-oncology portfolio for $508 million.

Novartis: In February 2025, Novartis agreed to acquire Anthos Therapeutics for approximately $925 million. In August 2023, Novartis successfully acquired Chinook Therapeutics for approximately $3.5 billion.

Recent Developments:

• The U.S. FDA authorized Ctexli from Mirum Pharmaceuticals in February 2025 for the treatment of cerebrotendinous xanthomatosis, a rare hereditary condition that affects cholesterol metabolism.
• Akeso has demonstrated an increasing interest in medication repurposing in oncology and autoimmune illnesses, and its work involves the development of PD-1/PD-L1 inhibitors for the treatment of cancer.

Conclusion

• Researchers and pharmaceutical businesses can make use of pre-existing safety profiles through drug repurposing, which reduces development time and boosts success rates.

Related Reports:

Drug Device Combination Products Market size was valued at USD 118.2 Billion in 2024 and the total Drug Device Combination Products Market size is expected to grow at a CAGR of 8.2% from 2025 to 2032, reaching nearly USD 222.04 Billion by 2032.

Drug Repurposing Market was valued at USD 35.33 Bn in 2024 is expected to grow at a CAGR of 4.9% from 2025 to 2032 and reach USD 51.80 Bn by the end of 2032.

About Us

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Navale IT park Phase 2,

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India.

+91 9607365656

[email protected]